$171.85 Million in Sales Expected for Core Laboratories N.V. (CLB) This Quarter

Equities research analysts forecast that Core Laboratories N.V. (NYSE:CLB) will post sales of $171.85 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Core Laboratories N.V.’s earnings. The highest sales estimate is $172.16 million and the lowest is $171.54 million. Core Laboratories N.V. reported sales of $149.54 million in the same quarter last year, which indicates a positive year over year growth rate of 14.9%. The business is expected to report its next quarterly earnings report on Wednesday, January 24th.

According to Zacks, analysts expect that Core Laboratories N.V. will report full-year sales of $171.85 million for the current financial year, with estimates ranging from $656.10 million to $660.12 million. For the next financial year, analysts anticipate that the business will post sales of $731.16 million per share, with estimates ranging from $719.09 million to $750.74 million. Zacks’ sales calculations are an average based on a survey of analysts that that provide coverage for Core Laboratories N.V..

Core Laboratories N.V. (NYSE:CLB) last released its quarterly earnings data on Monday, October 23rd. The oil and gas company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.04. The firm had revenue of $166.20 million for the quarter, compared to the consensus estimate of $160.94 million. Core Laboratories N.V. had a net margin of 12.06% and a return on equity of 52.89%. The firm’s revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.38 earnings per share.

A number of analysts recently commented on CLB shares. Royal Bank of Canada reissued a “buy” rating and set a $115.00 price objective on shares of Core Laboratories N.V. in a report on Friday, September 1st. Deutsche Bank AG started coverage on shares of Core Laboratories N.V. in a report on Tuesday, October 10th. They set a “buy” rating and a $109.00 price objective on the stock. Loop Capital decreased their price objective on shares of Core Laboratories N.V. from $125.00 to $115.00 and set a “buy” rating on the stock in a report on Wednesday, October 25th. ABN Amro upgraded shares of Core Laboratories N.V. from a “hold” rating to a “buy” rating in a research report on Wednesday, October 25th. Finally, ValuEngine upgraded shares of Core Laboratories N.V. from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $108.64.

Several large investors have recently bought and sold shares of CLB. BlackRock Inc. raised its position in shares of Core Laboratories N.V. by 3,736.4% in the first quarter. BlackRock Inc. now owns 1,598,608 shares of the oil and gas company’s stock valued at $184,672,000 after buying an additional 1,556,938 shares during the last quarter. Sustainable Growth Advisers LP raised its position in shares of Core Laboratories N.V. by 36.9% in the second quarter. Sustainable Growth Advisers LP now owns 2,345,271 shares of the oil and gas company’s stock valued at $237,505,000 after buying an additional 632,263 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Core Laboratories N.V. by 141.7% in the third quarter. Bank of New York Mellon Corp now owns 567,306 shares of the oil and gas company’s stock valued at $55,992,000 after buying an additional 332,620 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC raised its position in shares of Core Laboratories N.V. by 19.0% in the third quarter. Kayne Anderson Rudnick Investment Management LLC now owns 2,025,357 shares of the oil and gas company’s stock valued at $199,904,000 after buying an additional 323,357 shares during the last quarter. Finally, WCM Investment Management CA raised its position in shares of Core Laboratories N.V. by 7.3% in the second quarter. WCM Investment Management CA now owns 4,433,175 shares of the oil and gas company’s stock valued at $448,948,000 after buying an additional 303,073 shares during the last quarter.

ILLEGAL ACTIVITY NOTICE: “$171.85 Million in Sales Expected for Core Laboratories N.V. (CLB) This Quarter” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2017/11/11/171-85-million-in-sales-expected-for-core-laboratories-n-v-clb-this-quarter.html.

Core Laboratories N.V. (CLB) traded up $0.40 during mid-day trading on Wednesday, reaching $105.40. 518,400 shares of the company were exchanged, compared to its average volume of 558,766. The stock has a market capitalization of $4,635.47, a P/E ratio of 57.38 and a beta of 1.57. Core Laboratories N.V. has a 52-week low of $86.55 and a 52-week high of $125.83. The company has a current ratio of 2.18, a quick ratio of 1.81 and a debt-to-equity ratio of 1.53.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 21st. Stockholders of record on Friday, October 20th will be given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.09%. The ex-dividend date of this dividend is Thursday, October 19th. Core Laboratories N.V.’s dividend payout ratio is presently 126.44%.

Core Laboratories N.V. Company Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Get a free copy of the Zacks research report on Core Laboratories N.V. (CLB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Core Laboratories N.V. (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply